IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by LRI Investments LLC

LRI Investments LLC raised its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 3,542.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 23,823 shares of the medical research company's stock after purchasing an additional 23,169 shares during the period. IQVIA makes up about 0.5% of LRI Investments LLC's portfolio, making the stock its 28th largest holding. LRI Investments LLC's holdings in IQVIA were worth $5,645,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. First Foundation Advisors boosted its holdings in IQVIA by 3.8% in the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company's stock valued at $245,000 after acquiring an additional 43 shares during the last quarter. Invera Wealth Advisors LLC boosted its holdings in IQVIA by 0.3% during the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company's stock worth $3,183,000 after purchasing an additional 46 shares during the last quarter. Private Trust Co. NA increased its position in shares of IQVIA by 10.7% during the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company's stock valued at $115,000 after acquiring an additional 47 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its holdings in shares of IQVIA by 0.3% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company's stock worth $3,313,000 after buying an additional 48 shares during the last quarter. Finally, Continuum Advisory LLC boosted its stake in IQVIA by 3.3% in the second quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company's stock valued at $325,000 after acquiring an additional 49 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Stock Performance

NYSE IQV traded up $3.81 during trading hours on Monday, reaching $206.44. The stock had a trading volume of 1,748,849 shares, compared to its average volume of 1,182,642. The stock has a fifty day moving average of $215.18 and a 200 day moving average of $225.10. The stock has a market cap of $37.47 billion, a P/E ratio of 26.59, a price-to-earnings-growth ratio of 2.08 and a beta of 1.49. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73.

Analysts Set New Price Targets

Several analysts have recently issued reports on IQV shares. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a research report on Wednesday, December 4th. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a report on Friday, November 1st. Evercore ISI decreased their target price on shares of IQVIA from $270.00 to $265.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 8th. Barclays dropped their price objective on IQVIA from $260.00 to $255.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. Finally, Morgan Stanley lowered their price target on IQVIA from $280.00 to $265.00 and set an "overweight" rating for the company in a research report on Monday, November 4th. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $256.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.